Treatment of diverticular disease of the colon and prevention of acute diverticulitis: A systematic review

Diseases of the Colon and Rectum

Volumn 54, Issue 10, 2011, Pages 1326-1338

  Maconi, Giovanni ^a   Barbara, Giovanni ^b   Bosetti, Cristina ^c   Cuomo, Rosario ^d   Annibale, Bruno ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Colonic diverticular disease; Diverticulitis; Systematic review; Treatment

Indexed keywords

ANTIBIOTIC AGENT; MANNAN; MESALAZINE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN;

ACUTE DIVERTICULITIS; ANTIBIOTIC THERAPY; COLON DIVERTICULOSIS; DATA EXTRACTION; DIVERTICULITIS; DRUG EFFICACY; DRUG SAFETY; EMBASE; FIBER; HUMAN; MEDICAL HISTORY; MEDLINE; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; QUESTIONNAIRE; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COMBINED MODALITY THERAPY; DIETARY FIBER; DIVERTICULITIS, COLONIC; DIVERTICULUM, COLON; DRUG THERAPY, COMBINATION; HUMANS; MESALAMINE; PROBIOTICS; RIFAMYCINS;

EID: 80052707142     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e318223cb2b     Document Type: Review

References (68)

1. Munson KD, Hensien MA, Jacob LN, Robinson AM, Liston WA. Diverticulitis: a comprehensive follow-up. Dis Colon Rectum. 1996;39:318-324.
2. Parks TG. Natural history of diverticular disease of the colon. Clin Gastroenterol. 1975;4:53-69.
3. Almy TP, Howell DA. Medical progress: diverticular disease of the colon. N Engl J Med. 1980;302:324-331. (Pubitemid 10164145)
4. Jacobs DO. Clinical practice: diverticulitis. N Engl J Med. 2007; 357:2057-2066.
5. Ludeman L, Warren BF, Shepherd NA. The pathology of diver-ticular disease. Best Pract Res Clin Gastroenterol. 2002;16:543-562.
6. Petruzziello L, Iacopini F, Bulajic M, Shah S, Costamagna G. Review article: uncomplicated diverticular disease of the colon. Aliment Pharmacol Ther. 2006;23:1379-1391.
7. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology. 1988;95:232-241.
8. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med. 1999;107:91S-97S.
9. Brodribb AJ. Treatment of symptomatic diverticular disease with a high-fibre diet. Lancet. 1977;1:664-666. (Pubitemid 8121564)
10. Srivastava GS, Smith AN, Painter NS. Sterculia bulk-forming agent with smooth-muscle relaxant versus bran in diverticular disease. Br Med J. 1976;1:315-318.
11. Taylor I, Duthie HL. Bran tablets and diverticular disease. Br Med J. 1976;1:988-990.
12. Hodgson WJ. The placebo effect: is it important in diverticular disease? Am J Gastroenterol. 1977;67:157-162. (Pubitemid 8121747)
13. Eastwood MA, Smith AN, Brydon WG, Pritchard J. Comparison of bran, ispaghula, and lactulose on colon function in diverticular disease. Gut. 1978;19:1144-1147. (Pubitemid 9134501)
14. Ewerth S, Ahlberg J, Holmström B, Persson U, Udén R. Influence on symptoms and transit-time of Vi-SiblinR in diverticular disease. Acta Chir Scand Suppl. 1980;500:49-50. (Pubitemid 11214516)
15. Ornstein MH, Littlewood ER, Baird IM, Fowler J, North WR, Cox AG. Are fibre supplements really necessary in diverticular disease of the colon? A controlled clinical trial. Br Med J (Clin Res Ed). 1981;282:1353-1356. (Pubitemid 11057048)
16. Smits BJ, Whitehead AM, Prescott P. Lactulose in the treatment of symptomatic diverticular disease: a comparative study with high-fibre diet. Br J Clin Pract. 1990;44:314-318. (Pubitemid 20256002)
17. Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon: a pilot multicentre open trial. Diverticular Disease Study Group. Ital J Gastroenterol. 1992;24:452-456.
18. Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon: a multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther. 1995;9:33-39.
19. Trespi E, Panizza P, Colla C, Bottani G, De Vecchi P, Matti C. Efficacy of low dose mesalazine (5-ASA) in the treatment of acute inflammation and prevention of complications in patients with symptomatic diverticular disease: preliminary results [in Italian]. Minerva Gastroenterol Dietol. 1997;43:157-162. (Pubitemid 27414281)
20. Trepsi E, Colla C, Panizza P, et al. Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine: 4 year follow-up results [in Italian]. Minerva Gastroenterol Dietol. 1999;45:245-252. (Pubitemid 30084200)
21. Tursi A, Brandimarte G, Daffinà R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis. 2002;34:510-515. (Pubitemid 34830693)
22. Dughera L, Serra AM, Battaglia E, Tibaudi D, Navino M, Emanuelli G. Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension. Minerva Gastroenterol Dietol. 2004;50:149-153. (Pubitemid 39006350)
23. Di Mario F, Aragona G, Leandro G, et al. Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci. 2005;50:581-586. (Pubitemid 40543752)
24. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol. 2006; 40:312-316. (Pubitemid 44309523)
25. Latella G, Pimpo MT, Sottili S, et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis. 2003;18:55-62. (Pubitemid 36764140)
26. Colecchia A, Vestito A, Pasqui F, et al. Efficacy of long term cyclic administration of the poorly absorbed antibiotic rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol. 2007;13:264-269. (Pubitemid 46231330)
27. Comparato G, Fanigliulo L, Cavallaro LG, et al. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci. 2007; 52:2934-2941. (Pubitemid 47512549)
28. Comparato G, Fanigliulo L, Aragona G, et al. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? Dig Dis. 2007;25:252-259. (Pubitemid 350194179)
29. Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Aiello F. Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated di-verticulitis of the colon. Int J Colorectal Dis. 2007;22:1103-1108. (Pubitemid 47500254)
30. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci. 2007;52:671-674.
31. D'Incà R, Pomerri F, Vettorato MG, et al. Interaction between rifaximin and dietary fibre in patients with diverticular disease. Aliment Pharmacol Ther. 2007;25:771-779. (Pubitemid 46434919)
32. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. Hepatogastroenterology. 2008;55:916-920. (Pubitemid 351975955)
33. Painter NS, Almeida AZ, Colebourne KW. Unprocessed bran in treatment of diverticular disease of the colon. Br Med J. 1972;2: 137-140.
34. Brodribb AJ, Humphreys DM. Diverticular disease: three studies. Part II. Treatment with bran. Br Med J. 1976;1:425-428.
35. Lombardo L, Lapertosa G. The ambulatory medical treatment of colonic diverticulitis: an open clinico-endoscopic-histological study with rifaximin, a nonaminoglycoside enteric antibiotic [in Italian]. Recenti Prog Med. 1991;82:300-304.
36. Thorburn HA, Carter KB, Goldberg JA, Finlay IG. Does ispaghula husk stimulate the entire colon in diverticular disease? Gut. 1992;33:352-356.
37. Giaccari S, Tronci S, Falconieri M, Ferrieri A. Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Riv Eur Sci Med Farmacol. 1993;15: 29-34. (Pubitemid 24082637)
38. Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol. 2003;15:313-315. (Pubitemid 36337852)
39. Brandimarte G, Tursi A. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med Sci Monit. 2004;10: PI70-PI73. (Pubitemid 38787636)
40. Simpson J, Neal KR, Scholefield JH, Spiller RC. Patterns of pain in diverticular disease and the influence of acute diverticulitis. Eur J Gastroenterol Hepatol. 2003;15:1005-1010. (Pubitemid 37094301)
41. Murray CD, Emmanuel AV. Medical management of diverticular disease. Best Pract Res Clin Gastroenterol. 2002;16:611-620.
42. Trivedi CD, Das KM. Emerging therapies for diverticular disease of the colon. J Clin Gastroenterol. 2008;42:1145-1151.
43. Peppas G, Bliziotis IA, Oikonomaki D, Falagas ME. Outcomes after medical and surgical treatment of diverticulitis: a systematic review of the available evidence. J Gastroenterol Hepatol. 2007;22:1360-1368. (Pubitemid 47274598)
44. Tursi A. Acute diverticulitis of the colon - current medical therapeutic management. Expert Opin Pharmacother. 2004;5:55-59. (Pubitemid 38072718)
45. Di Mario F, Comparato G, Fanigliulo L, et al. Use of mesalazine in diverticular disease. J Clin Gastroenterol. 2006;40(7 suppl 3): S155-S159. (Pubitemid 44174911)
46. Stollman NH, Raskin JB. Diagnosis and management of diver-ticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1999;94:3110-3121.
47. Sheth AA, Longo W, Floch MH. Diverticular disease and diver-ticulitis. Am J Gastroenterol. 2008;103:1550-1556.
48. Stollman N, Raskin JB. Diverticular disease of the colon. Lancet. 2004;363:631-639. (Pubitemid 38264184)
49. Lohrmann C, Ghanem N, Pache G, Makowiec F, Kotter E, Langer M. CT in acute perforated sigmoid diverticulitis. Eur J Radiol. 2005;56:78-83. (Pubitemid 41316491)
50. Kaiser AM, Jiang JK, Lake JP, et al. The management of complicated diverticulitis and the role of computed tomography. Am J Gastroenterol. 2005;100:910-917. (Pubitemid 40592387)
51. Smith AN, Drummond E, Eastwood MA. The effect of coarse and fine Canadian Red Spring Wheat and French Soft Wheat bran on colonic motility in patients with diverticular disease. Am J Clin Nutr. 1981;34:2460-2463. (Pubitemid 12176079)
52. Payler DK, Pomare EW, Heaton KW, Harvey RF. The effect of wheat bran on intestinal transit. Gut. 1975;16:209-213.
53. Kirwan WO, Smith AN, McConnell AA, Mitchell WD, Eastwood MA. Action of different bran preparations on colonic function. Br Med J. 1974;4:187-189.
54. Hyland JM, Taylor I. Does a high fibre diet prevent the complications of diverticular disease? Br J Surg. 1980;67:77-79. (Pubitemid 10162598)
55. Painter NS. The high fibre diet in the treatment of diverticular disease of the colon. Postgrad Med J. 1974;50:629-635.
56. Leahy AL, Ellis RM, Quill DS, Peel AL. High fibre diet in symptomatic diverticular disease of the colon. Ann R Coll Surg Engl. 1985;67:173-174. (Pubitemid 15056889)
57. Heaton KW. Is bran useful in diverticular disease? Br Med J (Clin Res Ed). 1981;283:1523-1524. (Pubitemid 12235785)
58. Parks TG. The role of dietary fibre in the prevention and treatment of diseases of the colon. Proc R Soc Med. 1973;66:681-683.
59. Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Trichopoulos DV, Willett WC. A prospective study of alcohol, smoking, caffeine, and the risk of symptomatic diverticular disease in men. Ann Epidemiol. 1995;5:221-228.
60. Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Trichopoulos DV, Willett WC. A prospective study of diet and the risk of symptomatic diverticular disease in men. Am J Clin Nutr. 1994; 60:757-764. (Pubitemid 24327875)
61. Aldoori W, Ryan-Harshman M. Preventing diverticular disease: review of recent evidence on high-fibre diets. Can Fam Physician. 2002;48:1632-1637. (Pubitemid 35363587)
62. Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-333. (Pubitemid 43381675)
63. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.
64. Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther. 2007;25:1271-1281. (Pubitemid 46763454)
65. Jung HK, Choung RS, Locke GR III, et al. Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol. 2010;105: 652-661.
66. Horgan AF, McConnell EJ, Wolff BG, et al. Atypical diverticular disease: surgical results. Dis Colon Rectum. 2001;44:1315-1318. (Pubitemid 32845910)
67. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med. 2005;201:1205-1215. (Pubitemid 40629065)
68. Andrews CN, Petcu R, Griffiths T, et al. Mesalamine alters colonic mucosal proteolytic activity and fecal bacterial profiles in diarrhea-predominant irritable bowel syndrome [abstract]. Gastroenterology. 2008;4(suppl 1):A-548.